In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Prospective controlled trial testing the effect of physical training over myocardial perfusion disturbance and quality of life in patients with primary microvascular angina: a pilot study.

Session Poster session 4

Speaker Associate Professor Marcus Vinicius Simoes

Event : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Poster Session

Authors : MV Simoes (Ribeirão Preto,BR), EEV Carvalho (Ribeirão Preto,BR), JC Crescencio (Ribeirão Preto,BR), A Schmidt (Ribeirão Preto,BR), LFL Oliveira (Ribeirão Preto,BR), CQ Bertini (Ribeirão Preto,BR), PV Schwartzmann (Ribeirão Preto,BR), LW Ana (Ribeirão Preto,BR), GL Santi (Ribeirão Preto,BR), L Gallo-Jr (Ribeirão Preto,BR), JA Marin-Neto (Ribeirão Preto,BR)

M.V. Simoes1 , E.E.V. Carvalho1 , J.C. Crescencio1 , A. Schmidt1 , L.F.L. Oliveira1 , C.Q. Bertini1 , P.V. Schwartzmann1 , L.W. Ana1 , G.L. Santi1 , L. Gallo-Jr1 , J.A. Marin-Neto1 , 1Medical School of Ribeirão Preto - University of São Paulo, Brazil - Ribeirão Preto - Brazil ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 716

Background: Primary microvascular angina (PMA) is a common condition associated with quality of life (QoL) and physical capacity (PC) deterioration, allied to frequent angina recurrence. PMA is recognized as a condition in which pharmacological interventions yield poor results in the control of ischemia and angina symptoms.

Purpose: We aimed at evaluating the impact of physical training (PT) over the PC, QoL, and the extent of reversible myocardial perfusion defects (rMPD) in patients with PMA.

Methods: We prospectively investigated 32 patients with PMA, characterized by effort angina, normal coronary arteries at coronary angiography and ≥2 myocardial segments with rMPD at stress-rest Sestamibi-Tc99m myocardial perfusion SPECT (MPS). At baseline, patients underwent SF-36 QoL questionary, cardiopulmonary exercise test and MPS. After that, they were assigned to a PT-group (n=23, 56±9 years old, 11 males) and a Control-group (n=9, 53±7 years old, 8 males), which was constituted by patients that declined the invitation to participate in the PT program. The PT-patients were submitted to 1-hour aerobic exercise in treadmill, 3 times/week, moderate intensity (60–85% of peak-VO2), during 3-months. All patients in both groups were re-evaluated after 3-months, with the same methods used at baseline.

Results: From the baseline to the post-training condition, we observed, respectively: 1. Significant increase in the peak-Vo2 in the PT-group (19.1±4.3 to 21.4±5.2 ml/kg/min, p<0.001), but not in the Control-group (17.2±3.2 to 16.6±3.7 ml/kg/min, p>0.05); 2. Significant improvement in all the SF-36 scores in the PT-group, including pain (32.9±20 to 67.8±20%, p=0.0001), functional capacity (37.4±24.2 to 88.9±11.9%, p=0.0001) and general health status (46.9±26.4 to 73.5±25.1%, p=0.003), but no significant changes were detected in the Control-group; 3. Significant reductions of mean number of the rMPD (6.4±3.9 to 2.2±3.4, p=0.0001) and of the Stress-Rest difference score (7.9±6.9 to 2.7±4.3, p=0.0004) for the PT-group, but no change was seen in the Control-group for number of rMPD (5.6±3.9 to 3.3±4.7, p=0.18) or Stress-Rest difference score (5.5±5.3 to 4.9±7.0, p=0.56).

Conclusions: Physical training is associated to significant reduction of the reversible ischemic myocardial perfusion defects in patients with PMA. This positive effect was accompanied by significant improvement of the functional capacity and quality of life. The results of this pilot study indicate that physical training may constitute a relevant therapeutic strategy in patients with PMA.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are